Cargando…
Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests
BACKGROUND: : Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test perfor...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Abbott Laboratories. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770247/ https://www.ncbi.nlm.nih.gov/pubmed/35086043 http://dx.doi.org/10.1016/j.jcv.2022.105080 |
_version_ | 1784635326667423744 |
---|---|
author | Rodgers, Mary A Olivo, Ana Harris, Barbara J Lark, Chris Luo, Xinxin Berg, Michael G Meyer, Todd V Mohaimani, Aurash Orf, Gregory S Goldstein, Yitz Fox, Amy S Hirschhorn, Julie Glen, William B Nolte, Frederick Landay, Alan Jennings, Cheryl Moy, James Servellita, Venice Chiu, Charles Batra, Rahul Snell, Luke B Nebbia, Gaia Douthwaite, Sam Tanuri, Amilcar Singh, Lavanya de Oliveira, Tulio Ahouidi, Ambroise Mboup, Souleymane Cloherty, Gavin A |
author_facet | Rodgers, Mary A Olivo, Ana Harris, Barbara J Lark, Chris Luo, Xinxin Berg, Michael G Meyer, Todd V Mohaimani, Aurash Orf, Gregory S Goldstein, Yitz Fox, Amy S Hirschhorn, Julie Glen, William B Nolte, Frederick Landay, Alan Jennings, Cheryl Moy, James Servellita, Venice Chiu, Charles Batra, Rahul Snell, Luke B Nebbia, Gaia Douthwaite, Sam Tanuri, Amilcar Singh, Lavanya de Oliveira, Tulio Ahouidi, Ambroise Mboup, Souleymane Cloherty, Gavin A |
author_sort | Rodgers, Mary A |
collection | PubMed |
description | BACKGROUND: : Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. OBJECTIVES: : To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). STUDY DESIGN: : Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. RESULTS: : Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94–100% of sera from immune competent B.1.1.7 patients 15–26 days after symptom onset. CONCLUSIONS: : These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate. |
format | Online Article Text |
id | pubmed-8770247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Abbott Laboratories. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87702472022-01-20 Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests Rodgers, Mary A Olivo, Ana Harris, Barbara J Lark, Chris Luo, Xinxin Berg, Michael G Meyer, Todd V Mohaimani, Aurash Orf, Gregory S Goldstein, Yitz Fox, Amy S Hirschhorn, Julie Glen, William B Nolte, Frederick Landay, Alan Jennings, Cheryl Moy, James Servellita, Venice Chiu, Charles Batra, Rahul Snell, Luke B Nebbia, Gaia Douthwaite, Sam Tanuri, Amilcar Singh, Lavanya de Oliveira, Tulio Ahouidi, Ambroise Mboup, Souleymane Cloherty, Gavin A J Clin Virol Paper from the 21st ESCV meeting BACKGROUND: : Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and their impact on diagnostic test performance. OBJECTIVES: : To evaluate the capacity of Abbott molecular, antigen, and serologic assays to detect circulating SARS-CoV-2 variants, including all current variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta). STUDY DESIGN: : Dilutions of variant virus cultures (B.1.1.7, B.1.351, B.1.429, B.1.526.1, B.1.526.2, B.1.617.1, B.1.617.2, P.1, R.1 and control isolate WA1) and a panel of N = 248 clinical samples from patients with sequence confirmed variant infections (B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, B.1.526.1, B.1.526.2, P.1, P.2, R.1) were evaluated on at least one assay: Abbott ID NOW COVID-19, m2000 RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex molecular assays; the BinaxNOW COVID-19 Ag Card and Panbio COVID-19 Ag Rapid Test Device; and the ARCHITECT/Alinity i SARS-CoV-2 IgG and AdviseDx IgM assays, Panbio COVID-19 IgG assay, and ARCHITECT/Alinity i AdviseDx SARS-CoV-2 IgG II assay. RESULTS: : Consistent with in silico predictions, each molecular and antigen assay detected VOC virus cultures with equivalent sensitivity to the WA1 control strain. Notably, 100% of all tested variant patient specimens were detected by molecular assays (N = 197 m2000, N = 88 Alinity m, N = 99 ID NOW), and lateral flow assays had a sensitivity of >94% for specimens with genome equivalents (GE) per device above 4 log (85/88, Panbio; 54/57 Binax). Furthermore, Abbott antibody assays detected IgG and IgM in 94–100% of sera from immune competent B.1.1.7 patients 15–26 days after symptom onset. CONCLUSIONS: : These data confirm variant detection for 11 SARS-CoV-2 assays, which is consistent with each assay target region being highly conserved. Importantly, alpha, beta, gamma, and delta VOCs were detected by molecular and antigen assays, indicating that these tests may be suitable for widescale use where VOCs predominate. Abbott Laboratories. Published by Elsevier B.V. 2022-02 2022-01-20 /pmc/articles/PMC8770247/ /pubmed/35086043 http://dx.doi.org/10.1016/j.jcv.2022.105080 Text en © 2022 Abbott Laboratories Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Paper from the 21st ESCV meeting Rodgers, Mary A Olivo, Ana Harris, Barbara J Lark, Chris Luo, Xinxin Berg, Michael G Meyer, Todd V Mohaimani, Aurash Orf, Gregory S Goldstein, Yitz Fox, Amy S Hirschhorn, Julie Glen, William B Nolte, Frederick Landay, Alan Jennings, Cheryl Moy, James Servellita, Venice Chiu, Charles Batra, Rahul Snell, Luke B Nebbia, Gaia Douthwaite, Sam Tanuri, Amilcar Singh, Lavanya de Oliveira, Tulio Ahouidi, Ambroise Mboup, Souleymane Cloherty, Gavin A Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests |
title | Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests |
title_full | Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests |
title_fullStr | Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests |
title_full_unstemmed | Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests |
title_short | Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests |
title_sort | detection of sars-cov-2 variants by abbott molecular, antigen, and serological tests |
topic | Paper from the 21st ESCV meeting |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770247/ https://www.ncbi.nlm.nih.gov/pubmed/35086043 http://dx.doi.org/10.1016/j.jcv.2022.105080 |
work_keys_str_mv | AT rodgersmarya detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT olivoana detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT harrisbarbaraj detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT larkchris detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT luoxinxin detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT bergmichaelg detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT meyertoddv detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT mohaimaniaurash detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT orfgregorys detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT goldsteinyitz detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT foxamys detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT hirschhornjulie detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT glenwilliamb detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT noltefrederick detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT landayalan detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT jenningscheryl detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT moyjames detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT servellitavenice detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT chiucharles detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT batrarahul detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT snelllukeb detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT nebbiagaia detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT douthwaitesam detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT tanuriamilcar detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT singhlavanya detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT deoliveiratulio detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT ahouidiambroise detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT mboupsouleymane detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests AT clohertygavina detectionofsarscov2variantsbyabbottmolecularantigenandserologicaltests |